What are the FIB‑4 score thresholds that define low, intermediate, and high risk for significant or advanced fibrosis?

FIB-4 Score Thresholds for Fibrosis Risk Stratification

Use FIB-4 <1.3 to rule out advanced fibrosis in patients under 65 years, FIB-4 <2.0 for those 65 years and older, and FIB-4 >2.67 to identify high-risk patients requiring hepatology referral and further evaluation. 1

Risk Categories and Clinical Actions

Low Risk: FIB-4 <1.3 (or <2.0 if age ≥65 years)

• Negative predictive value ≥90% for excluding advanced fibrosis 2
• These patients can be reassessed every 1-3 years without immediate further workup 1
• Critical caveat: Despite high negative predictive value, FIB-4 will miss approximately 10% of individuals with advanced fibrosis 1
• Important exception: In patients with diabetes or BMI ≥30 kg/m², FIB-4 <1.3 significantly under-triages risk—these patients should proceed directly to elastography even with low FIB-4 scores 3

Intermediate Risk: FIB-4 1.3-2.67

• This indeterminate zone captures 30-40% of tested patients 2
• Two management options based on clinical context 1:
  1. Proceed directly to liver stiffness measurement (LSM) via vibration-controlled transient elastography (VCTE)—particularly recommended if FIB-4 approaches 2.67 or in high-risk conditions
  2. Implement 1-year lifestyle intervention with intensified cardiometabolic risk factor management, then retest FIB-4; if still elevated, proceed to elastography

High Risk: FIB-4 >2.67

• Positive predictive value 60-80% for advanced fibrosis 2
• Refer to hepatology for liver stiffness measurement or liver biopsy to confirm fibrosis stage 2, 4
• Alternative high-specificity threshold of FIB-4 ≥3.25 can be used when higher specificity is needed 5

Age-Specific Adjustments

The age 65 threshold adjustment is critical: patients ≥65 years should use FIB-4 <2.0 as the low-risk cutoff rather than <1.3 2, 1. This adjustment accounts for age-related changes in AST and platelet counts that can artificially elevate FIB-4 scores in older individuals.

Population-Specific Performance Limitations

FIB-4 performs suboptimally in specific populations 1:

• Elderly patients (creates false positives)
• Patients with type 2 diabetes (reduced accuracy)
• Patients with obesity (BMI ≥30 kg/m²)

In diabetes and obesity, the probability of liver stiffness ≥8 kPa is significantly higher at any given FIB-4 value compared to patients without these conditions 3. This means standard FIB-4 thresholds underestimate fibrosis risk in these metabolic populations.

Sequential Testing Strategy

The most accurate approach uses two-tier risk stratification 2:

1. First tier: Calculate FIB-4 (simple, inexpensive, widely available)
2. Second tier: For intermediate/high FIB-4 values, proceed to elastography (VCTE preferred, with LSM thresholds: <8 kPa low risk, 8-12 kPa intermediate, >12 kPa high risk) 4

This sequential strategy achieves 75-80% diagnostic accuracy while reducing the uncertainty area to <10% 6.

Common Pitfalls to Avoid

• Do not use FIB-4 alone in patients with diabetes or obesity—fast-track these patients to elastography regardless of FIB-4 value 3
• Do not forget age adjustment at 65 years—using 1.3 as the cutoff in elderly patients generates excessive false positives 1
• Do not assume FIB-4 <1.3 completely excludes advanced fibrosis—it misses ~10% of cases 1
• Do not rely on FIB-4 alone for definitive diagnosis—it is a screening tool requiring confirmatory testing in intermediate/high-risk ranges 2